05),而与胃癌的分化程度、TNM分期、浸润深度、淋巴结转移情况相关(P
分子靶向治疗在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的治疗中起着越来越重要的作用。肝细胞生长因子/c-MET(hepatocyte growth factor/c-MET,HGF/c-MET)信号通路在NSCLC的发生、发展及NSCLC患者对表皮生长因子受体抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)的耐药方面都起着重要的作用,其已经成为NSCLC分子靶向治疗的又一热点。c-MET扩增或过表达被认为可能是继EGFR和间变淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因之后,NSCLC又一特征性的基因突变。HGF/c-MET抑制剂也在临床前的研究中取得良好的抗肿瘤效果。近期公布的一些II期/III期临床研究的数据显示,HGF/c-MET抑制剂可以使部分c-MET扩增或过表达的NSCLC患者生存获益。因此,本文就HGF/c-MET抑制剂治疗NSCLC的研究进展做一综述。
目的探讨磷脂酰肌醇3激酶(PI3K)、蛋白激酶B(Akt)在胃癌组织及远端正常组织中的表达情况,分析其表达与胃癌临床病理特征之间的关系。方法应用免疫组化S-P法、逆转录聚合酶链反应(RT-PCR)检测60例胃癌组织和25例正常胃组织(距癌边缘10cm以上的胃组织)中PI3K、Akt蛋白及mRNA的表达。结果

PI3K、Akt在胃癌组织中的表达均明显高于在远端正常胃组织中的表达,差异有统计学意义(P<0.01),二者在胃癌组织中的表达均与胃癌的分化程度、TNM分期、浸润深度、淋巴结转移情况相关(P
The Selleck Dorsomorphin current

standard treatment option for advanced hepatocellular carcinoma(HCC) is sorafenib, but its clinical benefit is modest. In spite of many attempts, few drugs can provide any significant improvement of survival as the first- or second-line therapy of choice in phase Ⅲ randomized controlled trials. Recently, the subgroup analysis of a phase Ⅱ randomized controlled trial has shown that tivantinib, a selective MET inhibitor, can significantly selleck screening library improve the overall survival in patients with MET-positive advanced HCC after the failure or intolerance of a prior systemic therapy. These findings enlighten the role of MET inhibitors in the treatment of advanced HCC. In this paper, we review all ongoing and completed clinical trials regarding this topic. As for the first-line therapy of advanced HCC, INC280 and foretinib are being evaluated in 2 phase Ⅱ single-arm trials; and MSC2156119 J and golvatinib plus sorafenib are being compared with sorafenib alone in 2 phase

Ⅱ randomized controlled trials. As for the second-line therapy of advanced HCC, ARN509 tivantinib and cabozantinib are being compared with placebo in 2 phase Ⅲrandomized controlled trials.
The incidence of gastric cancer(GC) fell dramatically over the last 50 years, but according to IARC-Globocan 2008, it is the third most frequent cause of cancerrelated deaths with a case fatality GC ratio higher than other common malignancies. Surgical resection is the primary curative treatment for GC though the overall 5-year survival rate remains poor(approximately 20%-25%). To improve the outcome of resectable gastric cancer, different treatment strategies have been evaluated such as adjuvant or perioperative chemotherapy. In resected gastric cancer, the addition of radiotherapy to chemotherapy does not appear to provide any additional benefit.